We propose that therapeutic intervention centered on eliminating MYBL2 expression or inhibiting YAP/TAZ function as a consequence of dysregulated RhoA GTPase activity could be useful in preventing ADT resistance and blocking bone metastasis in PCa. The gene discussed is RHOA; the disease is posterior cortical atrophy.